X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs IPCA LABS - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH IPCA LABS STERLING BIOTECH/
IPCA LABS
 
P/E (TTM) x -0.4 29.0 - View Chart
P/BV x 0.0 4.3 0.3% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 STERLING BIOTECH   IPCA LABS
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
IPCA LABS
Mar-18
STERLING BIOTECH/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs11695 1.5%   
Low Rs3400 0.9%   
Sales per share (Unadj.) Rs26.8260.2 10.3%  
Earnings per share (Unadj.) Rs-15.019.0 -78.8%  
Cash flow per share (Unadj.) Rs-5.533.1 -16.5%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs54.9213.0 25.8%  
Shares outstanding (eoy) m267.87126.20 212.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.1 12.3%   
Avg P/E ratio x-0.528.9 -1.6%  
P/CF ratio (eoy) x-1.316.6 -7.7%  
Price / Book Value ratio x0.12.6 4.9%  
Dividend payout %05.3 0.0%   
Avg Mkt Cap Rs m1,86269,120 2.7%   
No. of employees `0001.413.3 10.2%   
Total wages/salary Rs m5477,359 7.4%   
Avg. sales/employee Rs Th5,303.32,477.4 214.1%   
Avg. wages/employee Rs Th403.8555.2 72.7%   
Avg. net profit/employee Rs Th-2,959.0180.6 -1,638.1%   
INCOME DATA
Net Sales Rs m7,18132,836 21.9%  
Other income Rs m43418 10.2%   
Total revenues Rs m7,22333,254 21.7%   
Gross profit Rs m9474,505 21.0%  
Depreciation Rs m2,5431,777 143.1%   
Interest Rs m4,377240 1,822.3%   
Profit before tax Rs m-5,9312,905 -204.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,924511 -376.5%   
Profit after tax Rs m-4,0072,394 -167.3%  
Gross profit margin %13.213.7 96.1%  
Effective tax rate %32.417.6 184.4%   
Net profit margin %-55.87.3 -765.2%  
BALANCE SHEET DATA
Current assets Rs m14,33519,455 73.7%   
Current liabilities Rs m49,80910,076 494.3%   
Net working cap to sales %-494.028.6 -1,729.5%  
Current ratio x0.31.9 14.9%  
Inventory Days Days40398 412.1%  
Debtors Days Days17167 254.9%  
Net fixed assets Rs m55,43220,260 273.6%   
Share capital Rs m268252 106.1%   
"Free" reserves Rs m13,93526,633 52.3%   
Net worth Rs m14,70126,886 54.7%   
Long term debt Rs m9,4782,340 405.0%   
Total assets Rs m73,98841,173 179.7%  
Interest coverage x-0.413.1 -2.7%   
Debt to equity ratio x0.60.1 740.7%  
Sales to assets ratio x0.10.8 12.2%   
Return on assets %0.56.4 7.8%  
Return on equity %-27.38.9 -306.0%  
Return on capital %-6.410.8 -59.7%  
Exports to sales %25.947.6 54.4%   
Imports to sales %0.214.9 1.1%   
Exports (fob) Rs m1,86015,642 11.9%   
Imports (cif) Rs m124,884 0.2%   
Fx inflow Rs m1,86015,642 11.9%   
Fx outflow Rs m254,884 0.5%   
Net fx Rs m1,83510,759 17.1%   
CASH FLOW
From Operations Rs m1,7193,411 50.4%  
From Investments Rs m-3,148-1,354 232.5%  
From Financial Activity Rs m1,426-1,304 -109.3%  
Net Cashflow Rs m-3753 -0.5%  

Share Holding

Indian Promoters % 33.9 45.9 73.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 11.4 -  
FIIs % 9.9 25.3 39.1%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 17.4 225.9%  
Shareholders   21,482 36,892 58.2%  
Pledged promoter(s) holding % 55.9 2.1 2,614.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   SANOFI INDIA  ABBOTT INDIA  PLETHICO PHARMA  DR. REDDYS LAB  TORRENT PHARMA  

Compare STERLING BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Dip After Record Rally; Sensex Ends 298 Points Lower(Closing)

It was a volatile day for Indian share markets today. The BSE Sensex and NSE Nifty opened at record high and went on to touch 40,000 and 12,000.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH - STRIDES PHARMA SCIENCE COMPARISON

COMPARE STERLING BIOTECH WITH

MARKET STATS